{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:46:12Z","timestamp":1791074772909,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":663,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The ideal treatment for patients who have failed eradication of <jats:italic>Helicobacter pylori<\/jats:italic> infection after standard proton pump inhibitor\u2010based triple therapies has still to be determined. Although either a second course of triple therapy or a quadruple therapy (proton pump inhibitor plus bismuth\u2010based triple therapy) has been proposed, the efficacy of these second\u2010line therapies is relatively unknown. Therefore, alternative strategies are needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To assess the efficacy and tolerability of rifabutin, a derivative of rifamycin\u2010S, in patients who were still <jats:italic>H. pylori<\/jats:italic> infected after two or more courses of 1\u2010week triple therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients were given a 1\u2010week regimen of pantoprazole 40\u2003mg b.d.\u2003+\u2003amoxycillin 1\u2003g b.d.\u2003+\u2003rifabutin 300\u2003mg daily. Side\u2010effects and compliance were determined at the end of therapy. Eradication rate was assessed with a <jats:sup>13<\/jats:sup>C\u2010urea breath test performed at 4 and 12\u2003weeks after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Forty\u2010one patients (mean age 47\u2003\u00b1\u200315\u2003years) were studied. All patients took medications according to the proposed schedule. Side\u2010effects were infrequent and mild. The eradication rates were 71% (95% CI: 57\u201385%) on intention\u2010to\u2010treat analysis and 74% (95% CI: 61\u201388%) on per protocol analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Rifabutin, in combination with pantoprazole and amoxycillin, is an effective and well tolerated regimen in patients who failed standard eradication treatments.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00719.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:41:09Z","timestamp":1047354069000},"page":"311-316","source":"Crossref","is-referenced-by-count":114,"title":["Rifabutin\u2010based \u2018rescue therapy\u2019 for <i>Helicobacter pylori<\/i> infected patients after failure of standard regimens"],"prefix":"10.1111","volume":"14","author":[{"family":"Perri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Quitadamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Andriulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199705000-00021"},{"key":"e_1_2_5_3_2","first-page":"8","article-title":"Current European concepts in the management of Helicobacter pylori infection","volume":"41","author":"The European Helicobacter pylori Study Group","year":"1997","journal-title":"The Maastricht Consensus Report Gut"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00504.x"},{"key":"e_1_2_5_5_2","first-page":"370","article-title":"Strategy for the re\u2010treatment of failed Helicobacter pylori eradication therapy: a case series","volume":"30","author":"Battaglia G","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709028149"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.96268000.x"},{"key":"e_1_2_5_8_2","first-page":"A98","article-title":"Two different approaches after failure of standard H. pylori eradication triple therapies","volume":"41","author":"Kusstatscher S","year":"1997","journal-title":"Gut"},{"key":"e_1_2_5_9_2","first-page":"A93","article-title":"Which therapy should we use when a previous Helicobacter pylori eradication therapy fails?","volume":"41","author":"Gisbert JP","year":"1997","journal-title":"Gut"},{"key":"e_1_2_5_10_2","first-page":"A96","article-title":"Maastricht consensus report regimen for second\u2010line treatment of H. pylori infection: how does it perform in practice?","volume":"41","author":"Goddard AF","year":"1997","journal-title":"Gut"},{"key":"e_1_2_5_11_2","first-page":"375","article-title":"Helicobacter pylori eradication failure: \u2018salvage\u2019 therapies needed","volume":"30","author":"Borody TJ","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_5_12_2","unstructured":"RossiR JabesD Della BrunaC.In vitroactivity of rifabutin a potential antibiotic in the therapy ofHelicobacter pylori. In: Abstract Book of the 6th International Congress for Infectious Diseases (ICID). Prague Czech Republic 1994: 69."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.40.3.353-b"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.459"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.3.473"},{"key":"e_1_2_5_16_2","first-page":"386","article-title":"Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin\u2014influence on treatment outcome","volume":"93","author":"Adamek RJ","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_17_2","first-page":"25","article-title":"Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation","volume":"48","author":"Megraud F","year":"1997","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.622"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2266"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447060-00008"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.Supplement_1.S3"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1997.tb00085.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018882804607"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","unstructured":"KubotaT SatoR MurakamiK et\u2003al.An increase in antibiotic\u2010resistantHelicobacter pyloristrains after new triple therapy. In: Abstract Book of DDW 1998. New Orleans LA 1998: A280.","DOI":"10.1016\/S0016-5085(98)80772-5"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92957-6"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199512000-00011"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80027-3"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00219.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.87259000.x"},{"key":"e_1_2_5_30_2","unstructured":"UngheriD Della BrunaC JabesD et\u2003al.LM 427: Further studies on the antimycobacterial activity. In: Proceedings of the 13th International Congress of Chemotherapy (ICC). Wien Austria 1983."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1497"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00719.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00719.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00719.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T16:38:23Z","timestamp":1698597503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00719.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00719.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00719.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}